Skip to main content
BioInvent International logo

BioInvent International — Investor Relations & Filings

Ticker · BINV ISIN · SE0015244520 LEI · 549300E7QRHEF2IJUY10 ST Manufacturing
Open in API
Filings indexed 679 across all filing types
Latest filing 2019-12-23 Regulatory Filings
Country SE Sweden
Listing ST BINV

About BioInvent International

https://www.bioinvent.com/en

BioInvent International is a clinical-stage company that discovers and develops novel, first-in-class immuno-modulatory antibodies for cancer therapy. Leveraging extensive expertise in immunology, cancer biology, and antibody biology, the company generates innovative immuno-oncology drug candidates for its clinical pipeline. BioInvent's operations include an in-house manufacturing facility to produce antibodies for its preclinical studies and clinical trials, with the goal of developing treatments that can transform the lives of cancer patients.

Recent filings

Filing Released Lang Actions
BioInvent meddelar val av andra målstrukturen samt förlängning av forskningssamarbetet och licensavtalet med Pfizer Inc.
Regulatory Filings Classification · 95% confidence The document is a press release dated December 23, 2019, announcing that Pfizer has selected a second target structure under an existing research collaboration and license agreement with BioInvent, and that the research period has been extended. It details a milestone payment ($300,000 USD) and mentions future potential milestone payments. This type of announcement, detailing a specific corporate transaction, partnership update, or financing event (like a milestone payment triggering under a license agreement), fits best under the 'Capital/Financing Update' (CAP) category if it involves significant capital movement or structure change, or potentially 'Regulatory Filings' (RNS) if it's a general disclosure. However, given the focus on a specific financial trigger (milestone payment) and the extension of a commercial agreement, it is a significant corporate/financing event announcement. Since it is not a full financial report (10-K, IR, ER), nor a management change (MANG), nor a dividend notice (DIV), nor a director dealing (DIRS), the most appropriate specific category for an update on a major licensing deal triggering payments is 'Capital/Financing Update' (CAP). It is a short announcement, not the underlying agreement itself, so RPA/RNS are secondary considerations, but CAP captures the essence of the financial trigger.
2019-12-23 Swedish
BioInvent Has Entered into a Clinical Trial Collaboration and Supply Agreement to Evaluate BI-1206 in Combination with KEYTRUDA[®] in Advanced Solid Tumors
Regulatory Filings Classification · 95% confidence The document is a press release dated December 18, 2019, announcing a clinical trial collaboration and supply agreement between BioInvent and MSD regarding the evaluation of BI-1206 in combination with KEYTRUDA® for advanced solid tumors. It details the nature of the agreement, the trial design (Phase I/IIa), and provides company background. The concluding paragraph states: "This information is information that BioInvent International AB is obliged to make public pursuant to the EU Market Abuse Regulation." This structure—a formal announcement of a significant corporate event (a partnership/trial initiation) released to the public market—is characteristic of a general regulatory announcement or press release that doesn't fit the specific financial report categories (like 10-K, ER, IR). Since it is a formal disclosure mandated by regulation (EU Market Abuse Regulation) but doesn't fit a more specific category like M&A (TAR) or Capital Change (CAP), the most appropriate general category is Regulatory Filings (RNS). The document length (3838 chars) is short, but it is the primary announcement itself, not an announcement *about* another report, so RPA is less suitable than RNS for this type of material event disclosure.
2019-12-18 English
BioInvent har ingått ett samarbets- och leveransavtal för en klinisk prövning för utvärdering av BI-1206 i kombination med KEYTRUDA[®] i avancerade solida tumörer
Regulatory Filings Classification · 90% confidence The document is a 'PRESSMEDDELANDE' (Press Release) dated December 18, 2019, announcing a 'samarbets- och leveransavtal' (collaboration and supply agreement) for a clinical trial involving BioInvent's drug candidate BI-1206 and MSD's KEYTRUDA®. This announcement details a strategic partnership and clinical development plan, which falls under corporate activities related to financing, partnerships, or major strategic moves. It is not a full financial report (10-K, IR), an earnings release (ER), or a formal regulatory filing like a DVA or DIRS. Since it describes a significant business agreement and clinical development strategy, it is best classified as a general corporate announcement. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for significant, non-standard corporate news that doesn't fit the specific partnership/M&A (TAR) or financing (CAP) codes, although it is a strategic announcement. However, looking closely at the definitions, this is a major business development announcement. Since there is no specific 'Partnership Agreement' or 'Clinical Trial Update' code, and it is a formal press release about a strategic deal, RNS (Regulatory Filings/General Announcement) is the safest general classification, as it is a mandatory public disclosure ('EU:s marknadsmissbruksförordning'). If 'TAR' (M&A Activity) were interpreted broadly to include major strategic alliances, it might fit, but this is a clinical collaboration, not a merger or takeover. Therefore, RNS is the most suitable general regulatory announcement category.
2019-12-18 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive quarterly financial report for BioInvent for the third quarter of 2019. It contains detailed financial statements (net sales, net income, cash flow), management commentary, operational highlights, and a pipeline status update. It is not a mere announcement (RPA) or a short release (ER), as it provides substantive financial data and analysis for the specified period. Q3 2019
2019-10-24 Swedish
Earnings Release 2019
Earnings Release Classification · 99% confidence The document contains detailed financial highlights for the 'Third quarter 2019' and 'January – September, 2019', along with extensive commentary on clinical trial progress, pipeline updates, and business focus. This structure—including quarterly financial figures, CEO commentary, and detailed operational updates for a period shorter than a full year—is characteristic of an Interim or Quarterly Report. It is comprehensive enough to be considered a full report for the period, not just a brief release (ER) or a mere announcement of a report (RPA). Key indicators: 'Third quarter 2019', 'January – September, 2019', detailed financial metrics (sales, loss after tax, cash flow), and clinical event summaries. This aligns perfectly with the definition of an Interim / Quarterly Report (IR). 9M 2019
2019-10-24 English
BioInvent signs manufacturing agreement with Cancer Research UK expected to generate approximately SEK 30 million (~$3 million)
Regulatory Filings Classification · 95% confidence The document is explicitly titled a "PRESS RELEASE" dated October 23, 2019. It announces a specific business event: BioInvent signing a manufacturing agreement with Cancer Research UK, detailing the financial terms (SEK 30 million) and the purpose (production of an antibody drug for clinical trials). This type of announcement, detailing a significant business development, partnership, or contract, is typically classified as a general regulatory announcement or a specific business update. Since it is not a formal financial report (10-K, IR, ER, MRQ), nor a management change (MANG), nor a capital action (CAP, SHA, POS), nor a proxy/governance document (DEF 14A, CGR), the most appropriate general category for a significant, non-standard business event announcement is Regulatory Filings (RNS), which serves as a broad category for official company news releases that don't fit elsewhere. The document length (7165 chars) is substantial enough that it is the primary announcement itself, not just a notice of publication (RPA).
2019-10-23 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.